Company announced preliminary Q4 2024 revenue of approximately $34.9 million and FY 2024 revenue of approximately $137.2 million, representing 12% year-over-year growth for the full year BILLERICA, Mass. / Jan 14, 2025 / Business Wire / Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced selected preliminary, unaudited results for the fourth... Read More

Complementary offerings will accelerate translation of biomarkers from research to the clinic driving new growth Expanded customer relationships and continuum of solution offerings maximize cross-selling opportunities across translational, academic and pharma applications Expects to generate approximately $40 million of annual cost synergies by the end of 2026 with path to positive free cash flow generation in 2026 Combined... Read More

BILLERICA, Mass. / Jan 02, 2025 / Business Wire / Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that President and Chief Executive Officer Masoud Toloue will present at the 43 rd Annual J.P. Morgan Healthcare Conference taking place January 13 th -16 th at the Westin St. Francis Hotel in San Francisco, CA. Quanterix’s presentation will... Read More

Builds technology capabilities through vertical integration of proprietary bead technology and drives OEM business BILLERICA, Mass. / Dec 17, 2024 / Business Wire / Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery and breakthrough diagnostics through ultrasensitive biomarker detection, today announced the acquisition of EMISSION iNC. (“EMISSION”). Quanterix expects the transaction will close in... Read More

BILLERICA, Mass. / Nov 22, 2024 / Business Wire / Quanterix Corporation (NASDAQ: QTRX) today announced that it received a notice (the “Notice”) on November 21, 2024 from The Nasdaq Stock Market LLC (“Nasdaq”) stating that because the Company has not yet filed its Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 (the “Form 10-Q"), it is no longer in compliance with Nasdaq Listing Rule 5250(c)(1) (the... Read More

Sixth Consecutive Quarter of Double-Digit Growth Reaffirms Full Year 2024 Outlook BILLERICA, Mass. / Nov 12, 2024 / Business Wire / Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced preliminary financial results for the third quarter ended September 30, 2024 and reaffirmed its full year 2024 guidance. The Company also disclosed the need... Read More

BILLERICA, Mass. / Nov 05, 2024 / Business Wire / Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that it will host a conference call on Tuesday, November 12, 2024, at 4:30 p.m. E.T., to discuss third quarter 2024 financial results. Quanterix will issue a press release regarding third quarter 2024 financial results prior to the... Read More

LucentAD TM Complete improves on single biomarker tests, significantly reducing the intermediate zone, providing results for more patients BILLERICA, Mass. / Oct 28, 2024 / Business Wire / Lucent Diagnostics, a brand of Quanterix Corporation (NASDAQ: QTRX), has introduced LucentAD Complete, a new multi-marker blood test designed to help detect Alzheimer’s Disease (AD) in a broader range of patients. Recent Alzheimer’s... Read More

BILLERICA, Mass. / Oct 02, 2024 / Business Wire / Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery and breakthrough diagnostics through ultrasensitive biomarker detection, today announced the appointment of Ivana Magovčević-Liebisch, Ph.D., J.D. to its Board of Directors. Dr. Magovčević-Liebisch brings more than 25 years of biopharmaceutical industry experience, including founding Vigil... Read More

Quanterix expands access to p-Tau 217 blood test kit using antibody technology licensed from Lilly BILLERICA, Mass. / Sep 30, 2024 / Business Wire / Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery and breakthrough diagnostics through ultrasensitive biomarker detection, today announced it is making its Simoa® p-Tau 217 Planar Kit commercially available as part of the next phase of Alzheimer’s... Read More

BILLERICA, Mass. / Aug 29, 2024 / Business Wire / Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that Chief Executive Officer Masoud Toloue and Chief Financial Officer Vandana Sriram will take part in a fireside chat at the Morgan Stanley 22 nd Annual Global Healthcare Conference on September 6, 2024 at 1:50 p.m. ET. The presentation... Read More

BILLERICA, Mass. / Aug 19, 2024 / Business Wire / Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery and breakthrough diagnostics through ultra-sensitive biomarker detection, today announced that it appointed Jeffrey Elliott to its Board of Directors. Mr. Elliott brings two decades of senior leadership experience in the medical diagnostics industry, including 8 years at Exact Sciences Corp., where... Read More

BILLERICA, Mass. / Aug 08, 2024 / Business Wire / Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced financial results for the second quarter ended June 30, 2024. “Our research business once again delivered strong performance in the second quarter, growing double digits,” said Masoud Toloue, Chief Executive Officer of Quanterix. “Demand... Read More

BILLERICA, Mass. / Aug 06, 2024 / Business Wire / Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced that Chief Executive Officer Masoud Toloue and Chief Financial Officer Vandana Sriram will speak in a fireside chat at the Canaccord Genuity 44th Annual Growth Conference on August 13, 2024, at 3:00 p.m., ET. The presentation will be... Read More

BILLERICA, Mass. / Jul 31, 2024 / Business Wire / Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that it will host a conference call on Thursday, August 8, 2024 at 4:30 p.m. E.T., to discuss its second quarter 2024 financial results. Quanterix will issue a press release regarding the second quarter 2024 earnings prior to the conference... Read More

Quanterix improves on its best-in-class p-Tau 217 standalone test with new multi-marker approach reducing the number of patients receiving uncertain results BILLERICA, Mass. / Jul 29, 2024 / Business Wire / Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today presented new data at the Alzheimer’s Association International Conference (AAIC), supporting... Read More

BILLERICA, Mass. / Jun 17, 2024 / Business Wire / Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that Chief Executive Officer, Masoud Toloue, and Chief Financial Officer, Vandana Sriram, will attend the Scotiabank Healthcare 1x1 Day on June 20, 2024. To learn more about Quanterix, visit www.quanterix.com/company . To learn more about... Read More

BILLERICA, Mass. / Jun 05, 2024 / Business Wire / Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that Chief Executive Officer Masoud Toloue will speak at the Goldman Sachs 45th Annual Global Healthcare Conference. Toloue will speak alongside Chief Financial Officer Vandana Sriram in a fireside chat presentation on Wednesday, June 12,... Read More

BILLERICA, Mass. / May 22, 2024 / Business Wire / Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that Chief Executive Officer Masoud Toloue will speak in a fireside chat at the 2024 Leerink Partners Healthcare Crossroads Conference. Quanterix’s presentation is scheduled for Wednesday, May 29, 2024, at 11:40 a.m. ET. The fireside chat... Read More

BILLERICA, Mass. / May 07, 2024 / Business Wire / Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced financial results for the first quarter ended March 31, 2024. “Building on the foundation our team developed last year, Quanterix is entering a new innovation and product delivery phase,” said Masoud Toloue, Chief Executive Officer of... Read More

BILLERICA, Mass. / Apr 29, 2024 / Business Wire / Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that it will host a conference call on Wednesday, May 8, 2024 at 8:30 a.m. E.T., to discuss its first quarter 2024 financial results. Quanterix will issue a press release regarding the first quarter 2024 earnings prior to the conference call... Read More

BILLERICA, Mass. / Mar 21, 2024 / Business Wire / Quanterix Corporation (NASDAQ: QTRX), a leading provider of ultra-sensitive research products and high-definition diagnostics, today announced a specific partnership path for laboratories interested in offering Tau based research and diagnostic testing services. Quanterix has secured over thirty U.S. patents protecting our innovative ultra-sensitive research products and... Read More

BILLERICA, Mass. / Mar 04, 2024 / Business Wire / Quanterix Corporation (NASDAQ: QTRX), a leading provider of ultra-sensitive research products and high-definition diagnostics, announced today that its Simoa ® phospho-Tau 217 (p-Tau 217) blood test has been granted Breakthrough Device designation by the U.S. Food and Drug Administration (FDA) as an aid in diagnostic evaluation of Alzheimer’s Disease (AD). The FDA’s... Read More

BILLERICA, Mass. / Feb 29, 2024 / Business Wire / Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced financial results for the fourth quarter and twelve months ended December 31, 2023. “The fourth quarter marked the successful completion of our corporate transformation. We now have a strong, scalable foundation for growth and innovation,”... Read More

BILLERICA, Mass. / Feb 26, 2024 / Business Wire / Quanterix Corporation (NASDAQ: QTRX) today announced that it has rescheduled the release of its financial results for the fourth quarter and year ended December 31, 2023 and the associated conference call in order to more closely align the release of such results with the filing of its Annual Report on Form 10-K for the year ended December 31, 2023, the deadline for which is... Read More

AdventHealth, Mass General Brigham, Mayo Clinic, MUSC, and UPMC will leverage Quanterix technology and assays to streamline care for Alzheimer’s patients BILLERICA, Mass. / Feb 26, 2024 / Business Wire / Quanterix Corporation (NASDAQ: QTRX), a leading provider of ultra-sensitive research products and high-definition diagnostics, today announced its first collaborations with health systems in pursuit of their shared goal to... Read More

BILLERICA, Mass. / Feb 23, 2024 / Business Wire / Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that Chief Executive Officer Masoud Toloue will present at Cowen’s 44th Annual Health Care Conference. Quanterix’s session will take place on Monday, March 4, 2024, at 12:50 p.m. EST and will be made available to attendees and, via webcast,... Read More

BILLERICA, Mass. / Feb 16, 2024 / Business Wire / Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced it will host a conference call on Tuesday, February 27, 2024, to discuss its fourth quarter earnings and full year 2023 financial results. The call will begin at 8:30 AM Eastern Time. It will be hosted by Masoud Toloue, the Company’s... Read More

BILLERICA, Mass. / Dec 12, 2023 / Business Wire / Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that President and Chief Executive Officer Masoud Toloue will present at the 42 nd Annual J.P. Morgan Healthcare Conference. Quanterix’s session will take place on Wednesday, January 10, 2024, at 5:15 p.m., PST. Webcast Information The live... Read More

BILLERICA, Mass. / Nov 13, 2023 / Business Wire / Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that President and Chief Executive Officer Masoud Toloue will speak in a fireside chat at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on Thursday, November 16, 2023 at 3:00 PM ET. To access the live... Read More

BILLERICA, Mass. / Nov 06, 2023 / Business Wire / Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced financial results for the three months ended September 30, 2023. Third Quarter Financial Highlights Revenue was $31.3 million, an 18% increase from $26.6 million for the corresponding prior year period. GAAP gross margin was 56.8% as... Read More

BILLERICA, Mass. / Oct 30, 2023 / Business Wire / Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that it will report financial results for the third quarter 2023 after the market closes on Monday, November 6, 2023, and will host a webcast and conference call on Tuesday, November 7, 2023 at 8:30 a.m. E.T. Click here to pre-register for... Read More

New test elevates the performance standard for blood biomarker tests intended for detecting amyloid pathology in individuals with cognitive impairment BILLERICA, Mass. / Oct 24, 2023 / Business Wire / Lucent Diagnostics, a diagnostics brand of Quanterix Corporation (NASDAQ: QTRX), today announced expansion of its LucentAD product line with the addition of a high accuracy p-Tau 217 blood test for Alzheimer’s disease –... Read More

Agreement provides Quanterix a license to extensively studied p-Tau 217 antibodies to enable global access to plasma-based testing for Alzheimer’s Disease research and diagnostics BILLERICA, Mass. / Oct 23, 2023 / Business Wire / Quanterix Corporation ( NASDAQ: QTRX), a leading provider of ultra-sensitive research products and high-definition diagnostics, today announced the signing of a license agreement with Janssen... Read More

BILLERICA, Mass. / Sep 28, 2023 / Business Wire / Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that Chief Executive Officer Masoud Toloue will speak on a panel at Goldman Sachs Alzheimer’s Disease Day on Tuesday, October 3, 2023. The panel, Infrastructure considerations: Outlook for blood-based testing, will be held at 12:15 p.m. ET... Read More

BILLERICA, Mass. / Sep 05, 2023 / Business Wire / Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that Chief Executive Officer Masoud Toloue will take part in a fireside chat at the Morgan Stanley 21 st Annual Global Healthcare Conference on September 13, 2023 at 3:35 p.m. ET. The presentation will be available virtually and participants... Read More

BILLERICA, Mass. / Aug 21, 2023 / Business Wire / Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery and breakthrough diagnostics through ultrasensitive biomarker detection, today announced that it appointed William (Bill) P. Donnelly to its Board of Directors. Mr. Donnelly brings many years of senior leadership experience in the life science tools industry, including 21 years at Mettler-Toledo... Read More

BILLERICA, Mass. / Aug 09, 2023 / Business Wire / Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery and breakthrough diagnostics through ultrasensitive biomarker detection, today announced that it has appointed Vandana Sriram, CPA, as Chief Financial Officer (CFO), effective August 21, 2023. Sriram replaces Michael Doyle, who has served as the Company’s CFO since July 2021. As previously announced,... Read More

BILLERICA, Mass. / Aug 07, 2023 / Business Wire / Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced financial results for the three months ended June 30, 2023. Second Quarter Financial Highlights Total revenue was $31.0 million versus prior year second quarter total revenue of $23.5 million, an increase of 32%. Second quarter revenue also... Read More

BILLERICA, Mass. / Aug 03, 2023 / Business Wire / Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that Chief Executive Officer Masoud Toloue will be presenting at the Canaccord Genuity 43rd Annual Growth Conference on August 10, 2023 at 12 p.m. EST. The presentation will be available virtually and participants can register here: here.... Read More

The company’s ultra-sensitive biomarker technology supports milestone achievement in establishing a method for clinicians to identify and interpret elevated values of sNfL in children and adolescents BILLERICA, Mass. / Jul 31, 2023 / Business Wire / Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery and breakthrough diagnostics through ultrasensitive biomarker detection, today announced that its... Read More

BILLERICA, Mass. / Jul 20, 2023 / Business Wire / Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that it will report financial results for the second quarter 2023 before the market opens on Tuesday, August 8, 2023, and will host a webcast and conference call on the same day at 8:30 a.m. E.T. Click here to pre-register for the conference... Read More

Test will play an important role in the evaluation of patients experiencing cognitive symptoms consistent with early signs of Alzheimer’s disease BILLERICA, Mass. / Jul 06, 2023 / Business Wire / Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery and breakthrough diagnostics through ultrasensitive biomarker detection, today announced it has launched LucentAD, a test to assist in the evaluation of... Read More

BILLERICA, Mass. / Jun 07, 2023 / Business Wire / Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that Chief Executive Officer Masoud Toloue will speak at the Goldman Sachs Annual Global Healthcare Conference on June 14, 2023 at 10:40 a.m., PT. The presentation will be available virtually and listeners can register here:... Read More

BILLERICA, Mass. / May 09, 2023 / Business Wire / Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced financial results for the three months ended March 31, 2023. “Our corporate transformation initiated in August 2022 to maximize Quanterix’s full potential is on track. We remain confident that we have taken the right steps to build a strong... Read More

BILLERICA, Mass. / May 02, 2023 / Business Wire / Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced it will host a conference call on Tuesday, May 9, 2023, to discuss its first quarter 2023 financial results. The call will begin at 4:30 PM Eastern Time. It will be hosted by Masoud Toloue, the Company’s President and Chief Executive... Read More

Blood-based measurement of neurofilament light chain (NfL) provides compelling evidence to support an accelerated drug approval by the FDA. The decision has positive implications for NfL blood testing as a key tool in neuro-drug development. BILLERICA, Mass. / Apr 25, 2023 / Business Wire / Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery and breakthrough diagnostics through ultrasensitive... Read More

BILLERICA, Mass. / Mar 08, 2023 / Business Wire / Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that Chief Executive Officer Masoud Toloue will present at Barclays Global Healthcare Conference on Wednesday, March 15, 2023 at 4:35 p.m., EDT. In addition, the company will also host in-person one-on-one meetings with institutional... Read More

BILLERICA, Mass. / Feb 28, 2023 / Business Wire / Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that Chief Executive Officer Masoud Toloue will present at Cowen’s 43rd Annual Health Care Conference. Quanterix’s session will take place on Tuesday, March 7, 2023, at 9:50 a.m. EST and will be made available to attendees and, via webcast,... Read More

BILLERICA, Mass. / Feb 24, 2023 / Business Wire / Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced it will host a conference call on Monday, March 6, 2023, to discuss its fourth quarter earnings and full year 2022 financial results. The call will begin at 8:30 AM Eastern Time. It will be hosted by Masoud Toloue, the Company’s President... Read More

Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that it has appointed Brian Blaser to its Board of Directors effective as of January 6, 2023. Mr. Blaser brings over 25 years of senior leadership experience in the in-vitro diagnostics industry, including 15 years at Abbott Laboratories where he was responsible for the company’s global... Read More

New CLIA blood test expands access to important “brain health” biomarker to advance research and clinical care Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery and breakthrough diagnostics through ultrasensitive biomarker detection, today announced the validation of a Laboratory Developed Test (LDT) to quantitatively measure neurofilament light chain (NfL) in serum as an aid in the evaluation of... Read More

Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that Chief Executive Officer Masoud Toloue will be presenting at the 41 st Annual J.P. Morgan Healthcare Conference. Quanterix’s session will take place on Thursday, Jan. 12, 2023, at 12 p.m., PST and will be made available to attendees and the general public. In addition to the session,... Read More